MicroPort® EP PathBuilderTM IceMagicTM Steerable Introducer Obtains Important NMPA Registration Approval

Shanghai, China, December 29 2020 — Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP”) has recently received registration approval from China’s National Medical Products Administration (“NMPA”) for its proprietary PathBuilderTM IceMagicTM Steerable Introducer.

The approved PathBuilderTM IceMagicTM Steerable Introducer is the first domestic product of its kind for use in conjunction with cryoablation balloons. It is also the first product in the cryoablation portfolio of MicroPort® EP to receive registration approval from NMPA. The certification of this product marks the further enrichment of MicroPort® EP’s product line in the field of complex arrhythmias, providing doctors and patients with diversified treatment options ranging from cryoablation to radiofrequency ablation.

Cryoballoon ablation is an innovative technique that has emerged in recent years for the treatment of atrial fibrillation (AF). Compared with traditional radiofrequency ablation methods, cryoballoon ablation has comparable effectiveness, fewer complications, shorter procedure duration, and is easily adopted by surgeons. In cryoballoon ablation, the PathBuilderTM IceMagicTM Steerable Introducer is used to establish endovascular access through the femoral vein and guide the cryoballoon catheter and circular mapping catheter to the left atrium. The introducer is a key device to ensure the success of the procedure through the precise placement and stable attachment of the balloon during cryoballoon ablation.

Going forward, MicroPort® EP will continue its commitment to improve its total solution platform of cardiac electrophysiology, which includes a combination of active and passive techniques as well as devices and equipment, to benefit even more patients with arrhythmias in China.